Profile
Ian Karp is currently Head-Investor Relations at Collegium Pharmaceutical, Inc. Former positions include Senior Director-Global Marketing at MedImmune LLC, Vice President & Head-Investor Relations at Shire Plc from 2016 to 2017, Senior Vice President-Investor & Public Relations at Karyopharm Therapeutics, Inc., and Senior Vice President-Corporate Communications at Intellia Therapeutics, Inc. Education includes an undergraduate degree from Emory University and an MBA from Rutgers Business School.
Ian Karp active positions
| Companies | Position | Start |
|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Investor Relations Contact | - |
Former positions of Ian Karp
| Companies | Position | End |
|---|---|---|
| SHIRE | Investor Relations Contact | 2017-11-30 |
| INTELLIA THERAPEUTICS, INC. | Public Communications Contact | - |
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Sales & Marketing | - |
| KARYOPHARM THERAPEUTICS INC. | Investor Relations Contact | - |
Training of Ian Karp
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Emory University
Emory University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Rutgers Business School
Rutgers Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel and potentially curative therapeutics | Health Technology |
- Stock Market
- Insiders
- Ian Karp
















